EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Glycaemic sugar metabolism and the gut microbiota: past, present and future

Florine H M Westerbeke iD, Ilias Attaye, Melany Rios-Morales, Max Nieuwdorp iD

The FEBS Journal · 2025-03 · 292 (6) · 1421-1436

DOI: 10.1111/febs.17293 ↗

At a glance

Übersichtsarbeit in The FEBS Journal, published online on 2024-10-02. Written by Florine H M Westerbeke and 3 co-authors. Institution: Department of Internal and Experimental Vascular Medicine, Amsterdam University Medical Centers, location AMC, The Netherlands. Major MEDLINE topics: Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Carbohydrate Metabolism. Cited 9 times so far (Crossref); 130 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, ZonMw.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Non‐communicable diseases (NCDs), such as type 2 diabetes (T2D) and metabolic dysfunction‐associated fatty liver disease, have reached epidemic proportions worldwide. The global increase in dietary sugar consumption, which is largely attributed to the production and widespread use of cheap alternatives such as high‐fructose corn syrup, is a major driving factor of NCDs. Therefore, a comprehensive understanding of sugar metabolism and its impact on host health is imperative to rise to the challenge of reducing NCDs. Notably, fructose appears to exert more pronounced deleterious effects than glucose, as hepatic fructose metabolism induces de novo lipogenesis and insulin resistance through distinct mechanisms. Furthermore, recent studies have demonstrated an intricate relationship between sugar metabolism and the small intestinal microbiota (SIM). In contrast to the beneficial role of colonic microbiota in complex carbohydrate metabolism, sugar metabolism by the SIM appears to be less beneficial to the host as it can generate toxic metabolites. These fermentation products can serve as a substrate for fatty acid synthesis, imposing negative health effects on the host. Nevertheless, due to the challenging accessibility of the small intestine, our knowledge of the SIM and its involvement in sugar metabolism remains limited. This review presents an overview of the current knowledge in this field along with implications for future research, ultimately offering potential therapeutic avenues for addressing NCDs.

Subjects

MeSH terms (MEDLINE)

Gastrointestinal MicrobiomeDiabetes Mellitus, Type 2Carbohydrate MetabolismHumansAnimalsFructoseGlucoseInsulin ResistanceIntestine, Small

Author keywords

gut microbiotanon‐communicable diseasessmall intestinal microbiotasmall intestinesugar metabolism

Substances

FructoseGlucose

Authors and institutions

  • Department of Internal and Experimental Vascular Medicine, Amsterdam University Medical Centers, location AMC, The Netherlands.

ORCID profiles: Florine H M Westerbeke, Max Nieuwdorp

Funding

  • Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers
  • ZonMw

Cite

APA

Westerbeke, F. H. M., Attaye, I., Rios-Morales, M., & Nieuwdorp, M. (2025). Glycaemic sugar metabolism and the gut microbiota: past, present and future. The FEBS Journal, 292(6), 1421-1436. https://doi.org/10.1111/febs.17293

Vancouver

Westerbeke FHM, Attaye I, Rios-Morales M, Nieuwdorp M. Glycaemic sugar metabolism and the gut microbiota: past, present and future. The FEBS Journal. 2025;292(6):1421-1436. doi:10.1111/febs.17293

BibTeX
@article{Westerbeke2025,
  author = {Westerbeke, Florine H M and Attaye, Ilias and Rios-Morales, Melany and Nieuwdorp, Max},
  title = {Glycaemic sugar metabolism and the gut microbiota: past, present and future},
  journal = {The FEBS Journal},
  year = {2025},
  volume = {292},
  number = {6},
  pages = {1421--1436},
  doi = {10.1111/febs.17293}
}
Start for free →